Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
APVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.40M
- P/E (TTM)
- 0.01
- EPS (TTM)
- $66.96
- Dividend yield
- None
- 52-week range
- 0.377 – 25.56
- Day range
- 0.3944 – 0.4249
- Volume / Avg
- 148.73K / 132.90K
- Beta
- —
- Shares outstanding
- 3.46M
52-week range
APVO stock today
Aptevo Therapeutics (APVO) closed at $0.4041 on Nov 20, down 2.37% (-$0.0098), versus the S&P 500's 3.70% decline. At this level, APVO sits near the bottom of its 52-week range of $0.377 to $25.56: 98.4% below the high and 7.2% above the low. Aptevo Therapeutics trades at 0.0x its trailing twelve-month earnings per share of $66.96.
Summary generated from market data by MetaCap's automated system. Methodology
About Aptevo Therapeutics
Company profileAptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jeffrey G. Lamothe CA
- Headquarters
- Seattle, WA
- Employees
- 33
- Website
- aptevotherapeutics.com
Financial highlights
Full financialsAptevo Therapeutics reported a net loss of $26.0 million, compared with a loss of $24.1 million a year earlier. Diluted earnings per share came in at -$87.27.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.11M | $12.29M |
| Growth | — | — | — | -74.67% | +185.26% |
| Net income | $-25.97M | $-24.13M | $-17.41M | $8.03M | $-28.46M |
| EPS (diluted) | $-87.27 | $-31,460.23 | $-2,316.83 | $1.57 | $-6.07 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$25.50+6210.32%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-5.19 vs $-3.72
- Surprise
- -39.52%
APVO news
All APVO news- Aptevo Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Mipletamig Clinical ProgressNasdaq
- Aptevo Therapeutics Presents Preclinical Data for APVO451, APVO452, and APVO711 at SITC 2026NasdaqAPVO, BRK.B
- Aptevo Therapeutics Inc. Reports Refined Priming-Dose Regimen for Mipletamig Ahead of Planned Phase 2 DevelopmentNasdaqAPVO, BRK.B
- Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell TransplantNasdaqAPVO, FRO
- Aptevo Therapeutics Inc. Amends Rights Agreement to Extend Expiration Date to October 23, 2027Nasdaq
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG DealsNasdaqAPVO, ASND, AZN, BIIB
Aptevo Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CAPSCapstone Holding Corp. | 1.44 | -9.15% | $1.35M | vs APVO |
| CMNDClearmind Medicine Inc. | 2.63 | -17.68% | $1.33M | vs APVO |
| ELABPMGC Holdings Inc. | 1.14 | -10.24% | $1.33M | vs APVO |
| ARTLArtelo Biosciences Inc. | 1.39 | -4.14% | $1.30M | vs APVO |
| JUNSJupiter Neurosciences Inc. | 1.24 | -18.75% | $1.63M | vs APVO |
| PRFXPRF Technologies Ltd. | 0.4758 | -23.68% | $1.66M | vs APVO |
| KALAKALA BIO Inc. | 2.71 | -10.28% | $1.74M | vs APVO |
| GOVXGeoVax Labs Inc. | 1.81 | -5.24% | $985.46K | vs APVO |
Indexes, lists and sector
Aptevo Therapeutics stock FAQ
What is Aptevo Therapeutics's stock price today?
APVO last traded at $0.4041 as of Nov 20, 4:00 PM EST, down 2.37% on the day. Prices are delayed at least 15 minutes.
What is APVO's P/E ratio?
APVO trades at a trailing P/E ratio of 0.01.
Who is Aptevo Therapeutics's CEO?
Mr. Jeffrey G. Lamothe CA is the chief executive officer of Aptevo Therapeutics Inc., which has about 33 employees.
What is the APVO 52-week high?
The 52-week high for APVO is $25.56 and the 52-week low is $0.377. The stock is currently 98.4% below its high.